Sanofi announces withdrawal, refiling of premerger notice on Provention Bio deal

Sanofi (SNY) announced today that it has withdrawn and refiled its Premerger Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with Sanofi’s pending acquisition of Provention Bio (PRVB). As previously announced on March 24, Sanofi commenced a cash tender offer to purchase all outstanding shares of common stock of Provention Bio for $25.00 per share, to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law. Sanofi has elected to withdraw and refile its Premerger Notification and Report Form, which was initially filed on March 24, to provide the Federal Trade Commission with additional time for review. Following such refiling, the waiting period under the HSR Act will expire at 11:59 P.M., Eastern Time, on April 25, the company noted. The acquisition is expected to close in the second quarter of 2023.